Uterine Leiomyomas: Safety and Efficacy of US-guided Suprapubic Transvaginal Radiofrequency Ablation at 1-year Follow-up.

Authors:
Qing Guo
Qing Guo
Dalian Institute of Chemical Physics
China
Hong-Yu Zhang
Hong-Yu Zhang
Huazhong Agricultural University
China

Radiology 2016 Jun 22;279(3):952-60. Epub 2015 Dec 22.

From the Department of Obstetrics and Gynecology (X.J.W., Q.G., L.X.T., H.Y.Z., Y.R.C.) and Department of Medical Research (B.L.G.), Shijiazhuang First Hospital, Hebei Medical University, 36 Fanxi Road, Shijiazhuang, Hebei Province, PR China 050011; and Department of Ultrasound, Beijing 309 Hospital, Beijing, China (B.S.C.).

Purpose To assess the safety and efficacy of ultrasonography (US)-guided suprapubic transvaginal (ST) radiofrequency ablation (RFA) in the treatment of symptomatic uterine leiomyomas at 1-year follow-up. Materials and Methods The institutional review board approved this prospective study, and all patients provided informed consent. ST RFA was performed as an outpatient procedure 3 days after menstruation in 51 women (age range, 32-52 years; mean age, 42.2 years) with 62 leiomyomas. The leiomyomas were assessed with conventional and contrast material-enhanced US before and after ST RFA for leiomyoma size, location, and blood flow. All patients were evaluated for postoperative complications, including abdominal pain, injury to surrounding tissues and organs, vaginal bleeding, increased vaginal discharge, fever, dyspnea, and menorrhagia, after ST RFA and at follow-up visits. The leiomyoma volumes, improvement in leiomyoma-related symptoms, effect on quality of life (QOL), and patient satisfaction were assessed and compared before and after ST RFA and at follow-up visits by using statistical analyses. Results Sixty-two leiomyomas were successfully treated with ST RFA until 90% of the leiomyoma was echogenic. At 1-month follow-up, 46 (74%) leiomyomas had no contrast enhancement, five (8%) had peripheral enhancement, eight (13%) had focal enhancement, and three (5%) had scattered enhancement at contrast-enhanced US. At 6-month follow-up, the number of leiomyomas that had no enhancement, peripheral enhancement, focal enhancement, or scattered enhancement was 43 (69%), seven (11%), nine (15%), and three (5%), respectively. The leiomyoma volumes were significantly (P < .05) reduced at 1-, 3-, 6-, and 12-month follow-up (from 33.0 cm(3) ± 25.1 [standard deviation] before treatment to 6.8 cm(3) ± 7.7 at 12-month follow-up). The mean percentage volume reduction at 1-, 3-, 6-, and 12-month follow-up was 28%, 57%, 63%, and 78%, respectively. The scores for symptoms and QOL were all significantly improved (P < .05) at follow-up, going from 45 ± 14 and 65 ± 41, respectively, before treatment to 0 and 100, respectively, at 12-month follow-up. No complications were reported during the periprocedural period or throughout follow-up. Most patients (41 of 45) were satisfied. Conclusion ST RFA may be an effective and safe alternative in the treatment of uterine leiomyomas. (©) RSNA, 2015 Online supplemental material is available for this article.

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2015142537DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
June 2016
15 Reads
6.870 Impact Factor

Publication Analysis

Top Keywords

12-month follow-up
16
follow-up
12
uterine leiomyomas
12
follow-up visits
8
enhancement
8
leiomyoma volumes
8
radiofrequency ablation
8
enhancement peripheral
8
peripheral enhancement
8
scattered enhancement
8
focal enhancement
8
rfa follow-up
8
transvaginal radiofrequency
8
1-year follow-up
8
safety efficacy
8
us-guided suprapubic
8
suprapubic transvaginal
8
rfa
7
leiomyomas
7
patient satisfaction
4

Similar Publications